Latest Stock Research & Market Analysis
Search All Research, Articles & Stock Profiles
ASX Stock Research
[BUY] WEB Travel Group (ASX: WEB): Near-Term Headwinds Create a Value Entry Point
Institutional sell-side rates WEB Travel Group a Buy with a 12-month price target of A$4.70. The stock closed at A$2.23 on 20 May 2026, implying roughly 111 per cent upside to that target. The bull case rests on three pillars: the hotel bed wholesaling sector is...
[BUY] Nick Scali (ASX: NCK): Margins, Growth and a Franked Yield
Institutional sell-side rates Nick Scali a Buy with a 12-month price target of around A$20. The stock closed at approximately A$14.47 on 9 May 2026, implying roughly 38 per cent upside before dividends. The thesis is built on three pillars: ANZ gross margins that sit...
[SELL] Macquarie Group (ASX: MQG) Why a 21% Rally Into Earnings Looks Stretched
Macquarie has rallied more than 21% in the past month, pushing the multiple to 24x forward earnings against a 10-year average of 16x. We walk through why the valuation looks stretched, the bull-case rebuttals (Aligned Data Centers, Qube), and why FY26 result on 8 May is the decision point.
[BUY] Nick Scali (ASX: NCK): Margins, Growth and a Franked Yield
Institutional sell-side rates Nick Scali a Buy with a 12-month price target of around A$20. The stock closed at approximately A$14.47 on 9 May 2026, implying roughly 38 per cent...
[SELL] Macquarie Group (ASX: MQG) Why a 21% Rally Into Earnings Looks Stretched
Macquarie has rallied more than 21% in the past month, pushing the multiple to 24x forward earnings against a 10-year average of 16x. We walk through why the valuation looks stretched, the bull-case rebuttals (Aligned Data Centers, Qube), and why FY26 result on 8 May is the decision point.
Global Marco and Market Research
Supply Shock to Knock the RBA Off the “Narrow Path” and Into the Rough
We held a positive outlook on the Australian macro earlier this year, but that view has been substantially undermined by the war in Iran. Surging fuel prices, rising interest rates, and the flow-on effects to cost-of-living pressures are now the dominant themes...
Gold Investment Primer and Why Gold Matters for Investors
The Gold Market and Why It Matters for Investors Gold is one of the most misunderstood assets in modern finance. It generates no cash flow, pays no dividend, and has limited industrial use compared to other metals. Yet it has preserved purchasing power across...
Energy Security After the Middle East Conflict and What It Means for Solar and Coal
Energy Security After the Middle East Conflict and What It Means for Solar and Coal The 2026 Middle East conflict has forced a global reassessment of energy security in ways that echo the 2022 European energy crisis but with broader implications. Three structural...
Global Stock Research
[HOLD] Tesla (NASDAQ: TSLA) A Strong Q1 But No Free Cash Flow Until 2028
Tesla (NASDAQ: TSLA) A Strong Q1 But No Free Cash Flow Until 2028 Tesla just delivered a first quarter result that was stronger than the market expected, with revenue beating the Street, automotive gross margins running well ahead of forecast, and energy storage...
[BUY] Corvus Pharmaceuticals (CRVS) – Novel and Differentiated Contender in Auto-Immune and Hematology
Corvus Pharmaceuticals has developed soquelitinib, a first-in-class oral ITK inhibitor targeting moderate-to-severe atopic dermatitis and relapsed/refractory peripheral T cell lymphoma. We initiate at Buy with a 12-month price target of $40.
[BUY] Broadcom (AVGO) – Three Hyperscaler Partnerships Lock In the Custom Silicon Growth Story
Broadcom has cemented its position as the dominant custom silicon and AI networking partner across the three largest US hyperscalers in the space of a single week. A long-term agreement with Google for next-generation TPUs, an expanded collaboration with Anthropic for...
[BUY] Corvus Pharmaceuticals (CRVS) – Novel and Differentiated Contender in Auto-Immune and Hematology
Corvus Pharmaceuticals has developed soquelitinib, a first-in-class oral ITK inhibitor targeting moderate-to-severe atopic dermatitis and relapsed/refractory peripheral T cell lymphoma. We initiate at Buy with a 12-month price target of $40.
[BUY] Broadcom (AVGO) – Three Hyperscaler Partnerships Lock In the Custom Silicon Growth Story
Broadcom has cemented its position as the dominant custom silicon and AI networking partner across the three largest US hyperscalers in the space of a single week. A long-term...
Region & Industry Outlook
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
ASX Announcement
James Hardie Industries plc (ASX: JHX) – James Hardie Q1 FY27 Results
James Hardie Industries has raised its full-year FY27 guidance following a stronger-than-expected first quarter, with pro forma adjusted EBITDA growth now targeted at 7.4 to 13.7 percent against prior expectations. The company reported net sales of $1.475 billion in...
Macquarie Technology Group (ASX: MAQ) – Macquarie Technology Completes Land Acquisition
Macquarie Technology Group has completed its acquisition of land in Macquarie Park for the proposed Macquarie Engineering and Technology Campus, marking a significant milestone in the company's infrastructure expansion strategy. The completion of this acquisition,...
IDX (ASX: IDX) – New Chief Executive and Managing Director Appointment
Integral Diagnostics Limited (ASX: IDX) has formally commenced the tenure of Jason Martinez as Managing Director and Chief Executive Officer on 6 August 2026, following the completion of his obligations to his previous employer. The appointment, which was announced to...
Macquarie Technology Group (ASX: MAQ) – Macquarie Technology Completes Land Acquisition
Macquarie Technology Group has completed its acquisition of land in Macquarie Park for the proposed Macquarie Engineering and Technology Campus, marking a significant milestone...
IDX (ASX: IDX) – New Chief Executive and Managing Director Appointment
Integral Diagnostics Limited (ASX: IDX) has formally commenced the tenure of Jason Martinez as Managing Director and Chief Executive Officer on 6 August 2026, following the...
Top Stock Reports
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Subscribe
Want more Free Research?
Subscribe today for free and get an alert when we have new research and webinars.
MF & Co. Asset Management
MF & Co. Asset Management is a boutique investment firm offering Equity Capital Markets and derivative general advice & trade execution services.
We are specialists in advising and trading in Australian and US Equities, Index & Equity Options and Options on Futures.
Contact
Get In Touch
Australia
1300 889 603
International
+61 2 8378 7199
M-F: 8am-5pm
Suite 803, Level 8
70 Pitt St, Sydney, NSW 2000